Production (Stage)
Neumora Therapeutics, Inc.
NMRA
$1.02
$0.209925.91%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -15.60% | 18.92% | -23.59% | -9.27% | 50.59% |
| Total Depreciation and Amortization | 0.00% | 0.64% | -2.50% | 1.27% | -4.82% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -7.91% | 2.15% | -17.00% | 62.68% | -90.01% |
| Change in Net Operating Assets | 61.28% | -104.61% | 425.85% | -351.55% | 127.39% |
| Cash from Operations | -18.09% | -50.34% | 40.38% | -30.74% | 16.50% |
| Capital Expenditure | -- | -- | -- | 100.00% | -1,661.36% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 144.35% | -163.43% | 638.59% | 114.24% | -1,187.57% |
| Cash from Investing | 144.70% | -162.93% | 638.59% | 114.17% | -1,196.74% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 774.03% | -33.84% | 43.85% | 444.25% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 200.00% | -- | -- | -- |
| Cash from Financing | -- | 917.18% | -42.31% | 43.85% | 483.58% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 88.55% | -206.82% | 487.72% | 83.13% | -399.69% |